Improving Red Blood Cell K-Uptake and its Impact on O2/CO2 Exchange, and No-Generation in Microvascular CHD: A Novel Therapeutic Approach

Recent Patents on Cardiovascular Drug Discovery

Volumn 5, Issue 3, 2010, Pages 227-238

  Delgado Almeida, Antonio ^a  

^a University of Carabobo Medical School   (Venezuela)

Author keywords

Hereditable defect in rbc k uptake; Oxygen unloading in cardiovascular diseases; Rbc and myocardial blood flow; Regulation of h k and o2 co2 exchange by rbc; Reversion of angina and st t alterations in chd

Indexed keywords

AMILORIDE DERIVATIVE; CARBON DIOXIDE; NITRIC OXIDE; OXYGEN;

ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY COLLATERAL CIRCULATION; ELECTROCARDIOGRAPHY; ERYTHROCYTE; GAS EXCHANGE; ISCHEMIC HEART DISEASE; OXYGEN CONSUMPTION; OXYGEN TRANSPORT; PATHOPHYSIOLOGY; POTASSIUM TRANSPORT; PRIORITY JOURNAL;

ANGINA PECTORIS; CARBON DIOXIDE; COLLATERAL CIRCULATION; CORONARY DISEASE; ERYTHROCYTES; HUMANS; MICROVESSELS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NITRIC OXIDE; OXYGEN; POTASSIUM;

EID: 78649985520     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489010793351890     Document Type: Article

References (95)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson G, Flegal K, et al. Heart disease and stroke statistics--2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics. Circulation 2009; 119: 480-6.
2. Leeder SR, Raymond S, Greenberg H. A race against time: The challenge of cardiovascular disease in developing economies. Sydney, Australia: Earth Institute at Columbia University 2004. http://www.earth.columbia.edu/news/2004/images/raceagainsttime
3. Jolicoeur EM, Granger CB, Henry TD, Holmes DJ, Pepine CJ, Mark D, et al. Working Group Members. Clinical and research issues regarding chronic advanced coronary artery disease: Part I: Contemporary and emerging therapies. Am Heart J 2008; 155: 418-34.
4. Schömig A, Mehilli J, de Waha A, Seyfarth M, Pache J, Kastrati A. A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52: 894-904.
5. Herman M, Donovan J, Tran M, McKenna B, Gore JM, Goldberg RJ, et al. Use of beta-blockers and effects on heart rate and blood pressure post-acute coronary syndromes: Are we on target? Am Heart J 2009; 158: 378-85.
6. Chokar, V. Combination therapy for coronary artery disease. US20070185065 (2007).
7. Hung, D.T., Annex, B.H., Landolfo, K.P., Kavanaugh, M.W. Method for inducing angiogenesis or vascular perfusion in the myocardium comprising administering fibroblast FGF-2. US7531511 (2009).
8. Boden W, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-16.
9. Curzen NP. Is there evidence for prognostic benefit following PCI in stable patients? COURAGE and its implications: An interventionalist's view. Heart 2010; 96: 103-5.
10. Weibel ER, Gomez DM. Architecture of the human lung. Science 1962; 137: 577-85.
11. Weibel ER. What makes a good lung? Swiss Med Wkly 2009; 139: 375-86.
12. Baroldi G, Mantero O, Scomazzoni G. The collaterals of the coronary arteries in normal and pathologic hearts. Circ Res 1956; 4: 223-9.
13. Baroldi G, Bigi R, Cortigiani L. Ultrasound imaging versus morphopathology in cardiovascular diseases. Coronary collateral circulation and atherosclerotic plaque. Cardiovasc Ultrasound 2005; 3: 6.
14. Fulton WF. Immersion radiography of injected specimens. Br J Radiol 1963; 36: 685-8.
15. Fulton WF. The dynamic factor in enlargement of coronary arterial anastomoses, and paradoxical changes in the subendocardial plexus. Br Heart J 1964; 26: 39-50.
16. Brinton TJ, Kailasam MT, Wu RA, Cervenka JH, Chio SS, Parmer RJ et al. Arterial compliance by cuff sphygmomanometer. Application to hypertension and early changes in subjects at genetic risk. Hypertension 1996; 28: 599-603.
17. Chio, S.S. Method for diagnosing, monitoring and treating hypertension and other cardiac problems. US6165130 (2000).
18. Delgado AJ, Delgado-Almeida A, Celis SI, Delgado-León C. Improved LV function, systemic vascular and brachial artery parameters in hypertension: The Venezuelan Telmisartan study. Am J Hypertens 2001; 14: 127A.
19. Lossnitzer K, Pfennigsdorf G, Brauer H. Myocardium Blood Vessels Calcium. Knoll AG, Ed. Ludwigshafen: Germany 1983.
20. Hinderling PH. Red blood cells: A neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 1997; 49: 279-95.
21. Jensen JB. Red blood cell pH, the Bohr Effect, and other oxygenation-linked phenomena in blood O2 and CO2 transport. Acta Physiol Scand 2004; 182: 215-27.
22. Van Slyke DD, Hastings AB, Heildelberger M, Neill JM. Studies of gas and electrolyte equilibria in the blood. III. The alkali-binding and buffer values of oxyhemoglobin and reduced hemoglobin. J Biol Chem 1922; 54: 481-506.
23. Van Slyke DD, Hastings AB, Neill JM. Studies of gas and electrolyte equilibria in the blood. IV. The effect of oxygenation and reduction on the bicarbonate content and buffer value of blood. J Biol Chem 1922; 54: 507-26.
24. Skalak R, Branemark PI. Deformation of red blood cells in capillaries. Science, (New Series) 1969; 164: 717-9.
25. Tomaiuolo G, Preziosi V, Simeone M, Guido S, Ciancia R, Martinelli V, et al. A methodology to study the deformability of red blood cells flowing in microcapillaries in vitro. Ann Ist Super Sanita 2007; 43: 186-92.
26. Delgado-Almeida A. Assessing cell K physiology in hypertensive patients. A new clinical and methodologic approach. Am J Hypertens 2006; 19: 432-6.
27. [Delgado-Almeida A, Delgado-León AJ, Delgado-León C. Changes in plasma ionized calcium and RBC K content in severe hyperkalemia: New electrocardiographic concept. Circulation 2006; 114: II-466.
28. Delgado-Almeida A, Delgado-León C, Delgado-León AJ. Reversion of ST-T alterations in hypertensives with LVH or coronary artery disease. Am J Hypertens 2004; 17: S189.
29. Delgado-Almeida A, Delgado-León C, Delgado-León AJ. Amiloride and red blood cell potassium transport in coronary artery disease: Reversion of the clinical and ECG alterations. Inter- American Society of Hypertension- XVIIth Scientific Meeting. Miami, USA 2007.
30. Pitt B, Pitt G. Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. Circulation 2007; 115: 2976-82.
31. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R on Behalf of the EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118: 1643-50.
32. Epstein M. Hyperkalemia as a constraint to therapy withcombination renin-angiotensin system blockade: The elephant in the room. J Clin Hypertens (Greenwich) 2009; 11: 55-60.
33. Ekundayo OJ, Adamopoulos C, Ahmed MI, Pitt B, Young JB, Fleg JL, et al. Oral potassium supplement use and outcomes in chronicheart failure: A propensity-matched study. Int J Cardiol 2010;14(2): 167-74.
34. Delgado MC, Delgado-Almeida A. Red blood cell K+ could be a marker of K+ changes in other cells involved in blood pressure regulation. J Hum Hypertens 2003; 17: 313-8.
35. Delgado MC, Delgado-Almeida A. Abnormal Potassium. In: Mohler III ER, Townsend RR, Eds. Advanced therapy in hypertension and vascular disease. BC Decker Inc. Publisher: Ontario, Canada 2006: 291-6.
36. Delgado-Almeida A, Delgado MC. Hereditability defect in red-cell K in hypertension. FASEB J 2008; 22: 968.
37. Delgado, M.C., Delgado-Almeida, A. Method for the diagnosis and treatment of conditions involving aberrant erythrocyte potassium levels. US20090274776 (2009).
38. Pietrzak M, Meyerhoff ME. Determination of potassium in red blood cells using unmeasured volumes of whole blood and combined sodium/potassium-selective membrane electrode measurements. Anal Chem 2009; 81: 5961-5.
39. Embury SH. The not-so-simple process of sickle cell vasoocclusion. Microcirculation 2004; 11: 101-13.
40. Araoz PA, Kirsch J, Primak AN, Braun NN, Saba O, Williamson EE. Optimal image reconstruction phase at low and high heart rates in dual-source CT coronary angiography. J Cardiovasc Imaging 2009; 25: 837-45.
41. Fuster V, Frye RL, Kennedy MA, Connolly DC, Mankin HT. The role of collateral circulation in the various coronary syndromes. Circulation 1979; 59:1137-44.
42. Cohen M, Rentrop KP. Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects: Prospective study. Circulation 1986; 74: 469-76.
43. Vyssoulis G, Kyriakidis M, Karpanou E, Kyriakidis C, Sfikakis P, Barbetseas J, et al. A prospective angiographic study of the coronary collateral circulation in coronary arterial disease. Int J Cardiol 1990; 21: 187-91.
44. Schwarz F, Flameng W, Ensslen R, Sesto M, Thormann J. Effect of coronary collaterals on left ventricular function at rest and during stress. Am Heart J 1978; 95: 570-7.
45. Kumbasar D, Akyürek O, Dincer I, Atmaca Y, Kilickap M, Erol C, et al. Good collaterals predict viable myocardium. Angiology 2007; 58: 550-5.
46. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009; 54: 281-92.
47. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: A review of mechanisms and therapies. Eur Heart J 2001; 22: 729-39.
48. Galiuto L, Lombardo A, Maseri A, Santoro L, Porto I, Cianflone D, et al. Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalization. Heart 2003; 89: 731-7.
49. Manoharan G, Ntalianis A, Muller O, Hamilos M, Sarno G, Melikian N, et al. Severity of coronary arterial stenoses responsible for acute coronary syndromes. Am J Cardiol 2009; 103: 1183-8.
50. Gibson CM, Schömig A. Coronary and myocardial angiography. Angiographic assessment of both epicardial and myocardial perfusion. Circulation 2004; 109(25): 3096-105.
51. Crnac J, Schmidt MC, Theissen P, Sechtem U. Assessment of myocardial perfusion by magnetic resonance imaging. Herz 1997; 22(1):16-28.
52. Wacker CM, Bauer WR. Myocardial microcirculation in humans - new approaches using MRI. Herz 2003; 28: 74-8.
53. Karamitsos TD, Leccisotti L, Arnold JR, Recio-Mayoral A, Bhamra-Ariza P, Howells RK, et al. Relationship between regional myocardial oxygenation and perfusion in patients with coronary artery disease: Insights from cardiovascular magnetic resonance and positron emission tomography. Circ Cardiovasc Imaging 2010; 3(1): 32-40.
54. Likoff W, Segal BL, Kasparian H. Paradox of normal selective coronary arteriograms in patients considered to have unmistakable coronary heart disease. N Engl J Med 1967; 276: 1063-6.
55. Bugiardini R, Merz BCN. Angina with normal coronary arteries: A changing philosophy. JAMA 2005; 293: 477-84.
56. Schwartz RS, Burke A, Farb A, Kaye D, Lesser JR, Henry TD, et al. Microemboli and microvascular obstruction in acute coronary thrombosis and sudden coronary death: Relation to epicardial plaque histopathology. J Am Coll Cardiol 2009; 54: 2167-73.
57. Ellsworth ML, Ellis CG, Goldman D, Stephenson AH, Dietrich HH, Sprague RS. Erythrocytes: Oxygen sensors and modulators of vascular tone. Physiology (Bethesda) 2009; 24: 107-16.
58. Brunton TL. On the use of nitrite of amyl in angina pectoris. Lancet 1867; 90: Issue 2291: 97-8.
59. den Uil CA, Lagrand WK, Spronk PE, van der Ent M, Jewbali LS, Brugts JJ, et al. Low-dose nitroglycerin improves microcirculation in hospitalized patients with acute heart failure. Eur J Heart Fail 2009; 11: 386-90.
60. Stern S, Bayes de Luna A. Coronary artery spasm: A 2009 update. Circulation 2009; 119: 2531-4.
61. Bin JP, Doctor A, Lindner J, Hendersen EM, Le DE, Leong-Poi H, et al. Effects of nitroglycerin on erythrocyte rheology and oxygen unloading: Novel role of S-nitrosohemoglobin in relieving myocardial ischemia. Circulation 2006; 113: 2502-8.
62. Crawford JH, Isbell TS, Huang Z, Shiva S, Chacko BK, Schechter AN. Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood 2006; 107: 566-74.
63. Ellsworth ML, Forrester T, Ellis CG, Dietrich HH. The erythrocyte as a regulator of vascular tone. Am J Physiol 1995; 269: 2155-61.
64. Nagababu E, Ramasamy S, Abernethy DR, Rifkind JM. Active nitric oxide produced in the red cell under hypoxic conditions by deoxyhemoglobin-mediated nitrite reduction. J Biol Chem 2003; 278: 46349-56.
65. Bohlen HG, Zhou X, Unthank JL, Miller SJ, Bills R. Transfer of nitric oxide by blood from upstream to downstream resistance vessels cause microvascular dilation. Am J Physiol Heart Circ Physiol 2009; 297: 1337-46.
66. Cao Z, Bell JB, Mohanty JG, Nagababu E, Rifkind JM. Nitrite enhances RBC hypoxic ATP synthesis and the release of ATP into the vasculature: A new mechanism for nitrite-induced vasodilation. Am J Physiol Heart Circ Physiol 2009; 297: 1494-503.
67. Clark MR. Senescence of red blood cells: progress and problems. Physiol Rev 1988; 68: 503-54.
68. Lew VL, Daw N, Etzion Z, Tiffert T, Muoma A, Vanagas L, et al. Effects of age-dependent membrane transport changes on the homeostasis of senescent human red blood cells. Blood 2007; 110: 1334-42.
69. Tiffert T, Daw N, Etzion Z, Bookchin RM, Lew VL. Age decline in the activity of the Ca2+ - sensitive K+ channel of human red blood cells. J Gen Physiol 2007; 129: 429-36.
70. He Q, Moonseong H, Heshka S, Wang J, Pierson Jr RN, Albu J, et al. Total body potassium differs by sex and race across the adult age span. Am J Clin Nutr 2003; 78: 72-7.
71. Caramelo C, Riesco A, Outeiriño J, Millás I, Blum G, Monzú B, et al. Effects of nitric oxide on red blood cells: Changes in erythrocyte resistance to hypotonic hemolysis and potassium efflux by experimental maneuvers that decrease nitric oxide. Biochem Biophys Res Commun 1994; 199: 447-54.
72. Bor-Kucukatay M, Wenby RB, Meiselman HJ, Baskurt OK. Effects of nitric oxide on red blood cell deformability. Am J Physiol Heart Circ Physiol 2003; 284: 1577-84.
73. Baskurt OK, Uyuklu M, Meiselman HJ. Protection of erythrocytes from sub-hemolytic mechanical damage by nitric oxide mediated inhibition of potassium leakage. Biorheology 2004; 41(2): 79-89.
74. Tsuda K, Kimura K, Nishio I, Masuyama Y. Nitric oxide improves membrane fluidity of erythrocytes in essential hypertension: An electron paramagnetic resonance investigation. Biochem Biophys Res Commun 2000; 275: 946-54.
75. Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. Semin Thromb Hemost 2003; 29: 435-50.
76. Konstantinova E, Ivanova L, Tolstaya T, Mironova E. Rheological properties of blood and parameters of platelets aggregation in arterial hypertension. Clin Hemorheol Microcirc 2006; 35: 135-8.
77. Abete P, Ferrara N, Cacciatore F, Madrid A, Bianco S, Calabrese C, et al. Angina-induced protection against myocardial infarction in adult and elderly patients: A loss of preconditioning mechanism in the aging heart? J Am Coll Cardiol 1997; 30: 947-54.
78. Boengler K, Schulz R, Heusch G. Loss of cardioprotection with ageing. Cardiovasc Res 2009; 83: 247-61.
79. Chiong MA, West RO, Parker JO. Influence of nitroglycerin on myocardial metabolism and hemodynamics during angina induced by atrial pacing. Circulation 1972; 45:1044-56.
80. Loscalzo, J., Vita, J.A., Loberg, M.D., Worcel, M. Transdermal patch composition for treating vascular diseases characterized by nitric oxide insufficiency. US7556824 (2009).
81. Rothbard, J.B., Mcgrane, P.L., Engleman, E.G., Fathman, G.C., Kreider, E. Compositions and methods for treating diseases. US7557087 (2009).
82. Blackburn, B., Belardinelli, L., Wolff, A. Use of ranolazine for the treatment of coronary microvascular diseases. US20080248112 (2008).
83. Luscher, T., Noll, G., Lerch, P. Method for treating unstable angina pectoris. US20040014654 (2004).
84. Barron, H.V., Botvinick, E. Method for treating occlusive peripheral vascular disease and coronary disease. US6440947 (2002).
85. Delgado-Almeida A. Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor. US20090062309 (2009).
86. Delgado-Almeida A. Critical value of the electrocardiogram in LVH: from predictive index to therapeutic reassessment. Hypertension 2005; 45: e6; author reply e6.
87. Delgado-Almeida A, Delgado-León C. Delgado AJ, Celis SI. SupraSystolic arterial pulse waveform analysis: New hemodynamic parameter for hypertension. Am J Hypertens 2002; 15: 73A.
88. Chio, S.S. Method for diagnosing, monitoring and treating hypertension and other cardiac problems. US6270461 (2001) and US6540687 (2003).
89. Chio SS, Tsai JJ, Hsu YM, Lapointe JC, Huynh-Covey T, DeMaria AN, et al. Development and validation of a noninvasive method to estimate cardiac output using cuff sphygmomanometry. Clin Cardiol 2007; 30: 615-20.
90. Kosmicki MA. Long-term use of short- and long-acting nitrates in stable angina pectoris. Curr Clin Pharmacol 2009; 4: 132-41.
91. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial. JAMA 2007; 297: 1775-83
92. Newby LK, Peterson ED. Does ranolazine have a place in the treatment of acute coronary syndromes? JAMA 2007; 297: 1823-5.
93. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects, Letter C (Principles for Medical Research Combined with Medical Care). 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Declaration of Helsinki. http://www.wma.net/en/30publications/10policies/b3/index.html
94. Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, et al. Rethinking randomized clinical trials for comparative effectiveness research: The need for transformational change. Ann Intern Med 2009; 151: 206-9.
95. Amilne C-P, Kaitin KI. Translational medicine: An engine of change for bringing new technology to community health. Sci Transl Med 2009; 1(5): 5cm5.